Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1 plus PD-1/PD-L1 monoclonal antibody in advanced biliary tract malignancies
CTR20251848Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in biliary cancer, sponsored by Biokin Pharmaceutical. Started Jun 2025; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20251848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251848.